Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
Article in The Lancet Respiratory Medicine (April 2021)
The most recent citing publications are shown below. View all 24 publications that cite this research output on Dimensions.
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience
Article in Journal of Cancer Research and Clinical Oncology (March 2021)
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
Article in Journal for ImmunoTherapy of Cancer (March 2021)